July 15, 2011
The Commonwealth Scientific and Industrial Research Organization (CSIRO), Australia’s national science agency, is considering extending animal trials of a genetically-modified (GM) wheat crop created with an artificially low glycemic index to humans, despite a lack of proper safety assessments. And a group of scientists and academics from around the world recently sent a joint letter to CSIRO explaining their “unequivocal denunciation” of the irresponsible proposal.
Created in partnership with Limagrain, Europe’s largest grain company and propagator of GMOs, the GM wheat has been tested on rats and pigs in Australia for a mere 28 days, which is not even close to enough time to observe the onset of adverse reactions and negative side effects. And yet the government there has granted approval for CSIRO to test the “Frankenwheat” on human subjects if it so chooses.
“The use of human subjects for these GM feeding experiments is completely unacceptable,” wrote the opposition group in their letter to CSIRO’s chief executive Megan Clark.” The experiments may be used to dispense with concerns about the health impacts of consuming GM plants, but will not in fact address the health risks GM plants raise.”
Such health risks, of course, include endocrine disruption, reproductive disorders and sterility, digestive problems, rapid aging, organ damage, autoimmune problems, insulin imbalances, and many others.
In truth, independent, long-term testing on the safety of any and all GMOs currently in the food supply has never taken place, and no GMO has ever been conclusively proven safe — every human currently consuming GMOs on a regular basis is actually an unwitting test subject in a giant biotechnology experiment (http://www.naturalnews.com/026426_G…).
“The feeding trials should not be conducted until long-term impact assessments have been undertaken and appropriate information released to enable the scientific community to determine the value of such research, as against the risks,” added the letter.
Letter signatories included Dr. Michael Antoniou of the gene expression and therapy group at King’s College London School of Medicine, and professor David Schubert from the Salk Institute for Biological Studies in California.
Sources for this story include:
This article was posted: Friday, July 15, 2011 at 3:33 am